Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Purpura, Thrombocytopenic, Idiopathic
View Full LandscapeTarget Indication
Purpura, Thrombocytopenic, Idiopathic
Clinical Trial
NCT00706342Last updated: 2/10/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tavlesse
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
View on EMA